C
Claire N. Harrison
Researcher at Guy's and St Thomas' NHS Foundation Trust
Publications - 511
Citations - 24605
Claire N. Harrison is an academic researcher from Guy's and St Thomas' NHS Foundation Trust. The author has contributed to research in topics: Ruxolitinib & Myelofibrosis. The author has an hindex of 66, co-authored 424 publications receiving 19843 citations. Previous affiliations of Claire N. Harrison include St Thomas' Hospital & National Health Service.
Papers
More filters
Journal ArticleDOI
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.
Holly L. Geyer,Bjorn Andreasson,Heidi E. Kosiorek,Amylou C. Dueck,Robyn M. Scherber,Kari A. Martin,Kristina A. Butler,Claire N. Harrison,Deepti Radia,Francisco Cervantes,Jean-Jacques Kiladjian,Andreas Reiter,Gunnar Birgegård,Francesco Passamonti,Zhenya Senyak,Alessandro M. Vannucchi,Chiara Paoli,Zhijian Xiao,Jan Samuelsson,Ruben A. Mesa +19 more
TL;DR: How sexuality symptoms from MPN relate to other patient characteristics, disease features, treatments, and symptoms is evaluated.
Journal ArticleDOI
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
Claire N. Harrison,Nicolaas Schaap,Alessandro M. Vannucchi,Jean-Jacques Kiladjian,Francesco Passamonti,Sonja Zweegman,Moshe Talpaz,Srdan Verstovsek,Shelonitda Rose,Jun Yi Zhang,Oumar Sy,Ruben A. Mesa +11 more
TL;DR: Evaluated data indicate that fedratinib 400 mg/day is safe and effective in patients with myelofibrosis and low pretreatment platelet counts, and no initial fedrat inib dose adjustment is required for these patients.
Journal ArticleDOI
The Medical Research Council PT1 Trial in Essential Thrombocythemia.
Anthony R. Green,Peter J. Campbell,Georgina Buck,Keith Wheatley,Clare L. East,David Bareford,Bridget S. Wilkins,Jon van der Walt,John T. Reilly,Claire N. Harrison +9 more
TL;DR: The MRC PT1 trial demonstrates that, compared to Hu+asp, Ag+asp is associated with an excess rate of arterial thrombosis, major hemorrhage and myelofibrotic transformation but decreased venous thromBosis, and suggest that Hu should remain first-line therapy in patients with ET at high risk for vascular events.
Journal ArticleDOI
Aspirin in low-risk essential thrombocythemia, not so simple after all?
TL;DR: It is concluded that antiplatelet therapy reduces the incidence of enous thrombosis in JAK2-positive patients and the rate of arterial hrombotic events in patients with associated cardiovascular risk factors; n the remaining low-risk patients observation may be an adequate ption.
Journal ArticleDOI
Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis
Stephen T. Oh,Ruben A. Mesa,Claire N. Harrison,Prithviraj Bose,Aaron T. Gerds,Mark L. Heaney,Vishal Gupta,Bart L. Scott,Jean-Jacques Kiladjian,Alessandro Lucchesi,S. Buckley,Shanthakumar R. Tyavanagimatt,Karisse Roman-Torres,John Mascarenhas,Srdan Verstovsek +14 more
TL;DR: Pacritinib is a potent ACVR1 inhibitor with a clinically important impact on transfusion independence in patients with myelofibrosis (MF) as discussed by the authors , which has been postulated that inhibition of activin A receptor, type I (ACVR1), which mediates hepcidin production, is able to overcome the JAK2 inhibitor class effect on anemia.